Zereunesay Desta

1.4k total citations
15 papers, 1.1k citations indexed

About

Zereunesay Desta is a scholar working on Pharmacology, Genetics and Oncology. According to data from OpenAlex, Zereunesay Desta has authored 15 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 7 papers in Genetics and 5 papers in Oncology. Recurrent topics in Zereunesay Desta's work include Pharmacogenetics and Drug Metabolism (11 papers), Estrogen and related hormone effects (7 papers) and Breast Cancer Treatment Studies (3 papers). Zereunesay Desta is often cited by papers focused on Pharmacogenetics and Drug Metabolism (11 papers), Estrogen and related hormone effects (7 papers) and Breast Cancer Treatment Studies (3 papers). Zereunesay Desta collaborates with scholars based in United States and Switzerland. Zereunesay Desta's co-authors include Anne Nguyen, D. A. Flockhart, David A. Flockhart, Todd C. Skaar, Lijun Wu, A. M. Storniolo, Yan Jin, L LI, Brant R. Ward and D M Nikoloff and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Zereunesay Desta

15 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zereunesay Desta United States 11 492 469 458 164 161 15 1.1k
Suzanne Lemler United States 11 729 1.5× 664 1.4× 433 0.9× 190 1.2× 283 1.8× 11 1.6k
DM Roden United States 7 278 0.6× 72 0.2× 312 0.7× 64 0.4× 48 0.3× 8 1.1k
Sony Tuteja United States 20 109 0.2× 123 0.3× 283 0.6× 73 0.4× 62 0.4× 71 1.3k
MV Relling United States 11 259 0.5× 209 0.4× 697 1.5× 88 0.5× 70 0.4× 13 1.3k
Roseann S. Gammal United States 14 229 0.5× 173 0.4× 976 2.1× 230 1.4× 35 0.2× 28 1.4k
Kathryn A. Phillips United States 6 128 0.3× 375 0.8× 282 0.6× 43 0.3× 119 0.7× 8 984
Alison E. Fohner United States 18 145 0.3× 148 0.3× 322 0.7× 107 0.7× 20 0.1× 47 962
Andrew D. Morris United Kingdom 25 577 1.2× 139 0.3× 144 0.3× 87 0.5× 120 0.7× 35 2.3k
JS Leeder United States 10 245 0.5× 451 1.0× 1.3k 2.9× 386 2.4× 27 0.2× 10 2.3k
Jean Combalbert France 12 125 0.3× 316 0.7× 579 1.3× 282 1.7× 31 0.2× 14 1.8k

Countries citing papers authored by Zereunesay Desta

Since Specialization
Citations

This map shows the geographic impact of Zereunesay Desta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zereunesay Desta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zereunesay Desta more than expected).

Fields of papers citing papers by Zereunesay Desta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zereunesay Desta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zereunesay Desta. The network helps show where Zereunesay Desta may publish in the future.

Co-authorship network of co-authors of Zereunesay Desta

This figure shows the co-authorship network connecting the top 25 collaborators of Zereunesay Desta. A scholar is included among the top collaborators of Zereunesay Desta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zereunesay Desta. Zereunesay Desta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Masters, Andrea R., Brandon T. Gufford, Jessica Bo Li Lu, et al.. (2016). Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. Journal of Pharmacology and Experimental Therapeutics. 358(2). 230–238. 28 indexed citations
2.
Kadakia, Kunal C., Claire Snyder, Kelley M. Kidwell, et al.. (2016). Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. The Oncologist. 21(5). 539–546. 61 indexed citations
3.
Robarge, Jason, Zereunesay Desta, Anne Nguyen, et al.. (2016). Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 161(3). 453–461. 10 indexed citations
4.
Hertz, Daniel L., Kelley M. Kidwell, Nicholas J. Seewald, et al.. (2016). Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. The Pharmacogenomics Journal. 17(6). 521–527. 21 indexed citations
5.
Michaud, Véronique, et al.. (2013). Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. The Pharmacogenomics Journal. 14(2). 151–159. 16 indexed citations
6.
Henry, N. Lynn, Faouzi Azzouz, Zereunesay Desta, et al.. (2012). Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer. Journal of Clinical Oncology. 30(9). 936–942. 284 indexed citations
7.
Henry, N. Lynn, James M. Rae, Lang Li, et al.. (2009). Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Research and Treatment. 117(3). 571–575. 55 indexed citations
8.
Desta, Zereunesay, L LI, Todd C. Skaar, et al.. (2006). Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clinical Pharmacology & Therapeutics. 80(1). 61–74. 371 indexed citations
9.
Stearns, Vered, Daniel F. Hayes, Yan Jin, et al.. (2004). The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxife. Journal of Clinical Oncology. 22(14_suppl). 508–508. 1 indexed citations
10.
Stearns, Vered, Michael D. Johnson, James M. Rae, et al.. (2004). RESPONSE: Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine. JNCI Journal of the National Cancer Institute. 96(11). 884–885. 3 indexed citations
11.
Desta, Zereunesay, et al.. (2002). The Gastroprokinetic and Antiemetic Drug Metoclopramide Is a Substrate and Inhibitor of Cytochrome P450 2D6. Drug Metabolism and Disposition. 30(3). 336–343. 86 indexed citations
12.
Desta, Zereunesay, et al.. (1999). Commentary on McIntyre IM, King CV, Staikos V, Gall J, Drummer OH. A Fatality Involving Moclobemide, Sertraline and Pimozide. J Forensic Sci 1997;42:951–53. Journal of Forensic Sciences. 44(1). 231–232. 7 indexed citations
13.
Desta, Zereunesay, Thomas Kerbusch, & D. A. Flockhart. (1999). Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clinical Pharmacology & Therapeutics. 65(1). 10–20. 92 indexed citations
14.
Desta, Zereunesay, David Thacker, Nadia Soukhova, Jennifer H. Shin, & D. A. Flockhart. (1999). Identification and characterization of human cytchrome P450 (CYP) isoforms interacting with cisapride. Clinical Pharmacology & Therapeutics. 65(2). 126–126. 2 indexed citations
15.
Desta, Zereunesay, et al.. (1998). Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6.. PubMed. 26(8). 775–8. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suzanne Lemler Breakdown of academic impact, for papers by DM Roden Breakdown of academic impact, for papers by Sony Tuteja Breakdown of academic impact, for papers by MV Relling Breakdown of academic impact, for papers by Roseann S. Gammal Breakdown of academic impact, for papers by Kathryn A. Phillips Breakdown of academic impact, for papers by Alison E. Fohner Breakdown of academic impact, for papers by Andrew D. Morris Breakdown of academic impact, for papers by JS Leeder Breakdown of academic impact, for papers by Jean Combalbert
Rankless by CCL
2026